22:15 , Sep 21, 2018 |  BC Extra  |  Clinical News

GTx shares crater after incontinence readout

GTx Inc. (NASDAQ:GTXI) shed 92% of its value Friday, falling from the small cap band to trading at roughly the value of its cash, after the company's enobosarm (GTx-024) failed in the Phase II ASTRID...
22:35 , Sep 20, 2018 |  BC Extra  |  Company News

Management tracks: Garland to lead Portola; Gallagher joining Abingworth

Hematology company Portola Pharmaceuticals Inc. (NASDAQ:PTLA) hired Scott Garland as president and CEO. He replaces CEO Bill Lis, who retired Aug. 1. Interim Co-Presidents John Curnutte, the company’s head of R&D, and Mardi Dier, its...
22:10 , Sep 17, 2018 |  BC Extra  |  Company News

Management tracks: Ultragenyx, Epizyme

Rare and ultra-rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) appointed Wladimir Hogenhuis as COO. Previously, he was SVP and general manager, specialty franchise at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Epizyme Inc. (NASDAQ:EPZM) said CBO Susan Graf will...
23:08 , Aug 10, 2018 |  BioCentury  |  Finance

Takeda gets Ambys-tious

After a two-year search, Takeda Pharmaceutical Co. Ltd.’s equity investment and option deal with newco Ambys Medicines finally gets the ball rolling on the pharma’s goal of building a liver franchise within its core area...
17:38 , Jul 20, 2018 |  BC Week In Review  |  Financial News

IFM launches subsidiary with $31M series A

IFM Therapeutics LLC (Boston, Mass.) launched inflammatory disease-focused subsidiary IFM Tre Inc. with a $31 million series A round co-led by Atlas Venture, Abingworth, Bristol-Myers Squibb Co. (NYSE:BMY) and IFM’s management. IFM Tre will develop three...
20:38 , Jul 19, 2018 |  BC Extra  |  Financial News

IFM launches subsidiary with $31M series A

IFM Therapeutics LLC (Boston, Mass.) launched inflammatory disease-focused subsidiary IFM Tre Inc. with a $31 million series A round co-led by Atlas Venture, Abingworth, Bristol-Myers Squibb Co. (NYSE:BMY) and IFM’s management. IFM Tre will develop three...
18:56 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Abingworth's BioVentures VII fund closes at $315M, exceeding target

Abingworth Management Ltd. closed its BioVentures VII fund at $315 million, exceeding the fund's $300 million target. Funds will be invested in the U.S. and Europe. Abingworth's therapeutic interests for BioVentures VII include next-generation cell therapies,...
18:49 , Jul 13, 2018 |  BioCentury  |  Finance

Curating Abingworth

With a narrower set of investment strategies and a diversified LP base for its latest fund, Abingworth is seeking double digit returns from the $315 million Bioventures VII. Abingworth’s Kurt von Emster told BioCentury the...
23:35 , Jul 9, 2018 |  BC Extra  |  Financial News

Abingworth closes BioVentures VII fund at $315M

Abingworth Management Ltd. closed its BioVentures VII fund at $315 million, exceeding the fund's $300 million target. Funds will be invested in the U.S. and Europe. Abingworth's therapeutic interests for BioVentures VII include next-generation cell therapies,...
16:42 , Jun 8, 2018 |  BC Week In Review  |  Financial News

SutroVax adds Slaoui as chairman, raises $85M series C

SutroVax Inc. (South San Francisco, Calif.) raised $85 million in an oversubscribed series C round led by new investor TPG on a newsy June 7 that also saw the vaccine company appoint Moncef Slaoui chairman...